Again, not major, but would you like to tell us about what is worth mentioning? Yeah, I

think.

So I think the really interesting data that came out last year was the combination data for BRCA patients in metastatic hormone sensitive.

The amplitude study suggested that the combination of niraparib and abiraterone had an improved radiographic progression survival.

It's not yet a mature study, but we are now... suggesting that people should have BRCA testing before when they present with high-volume metastatic disease, because I think that there will be an option to use combination treatment for people who present with metastatic hormones sensitive.

At the moment, that license isn't available, but it clearly will be coming down the line.

And that's a signal of the direction of travel rather than quite a firm recommendation at the moment.

Can you also give us some insights on this? So, of course,